Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    KL1333
Previous Study | Return to List | Next Study

A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03888716
Recruitment Status : Recruiting
First Posted : March 25, 2019
Last Update Posted : March 25, 2019
Sponsor:
Information provided by (Responsible Party):
NeuroVive Pharmaceutical AB

Brief Summary:
This will be a double blind, randomised, placebo controlled, single and multiple oral dose study conducted in 3 parts: Part A, Part B and Part C. Part A and Part B include healthy volunteers only and will be completed before Part C including patients with primary mitochondrial disease will be initiated. The starting dose in the first cohort of Part A will be 25 mg. The dose level in the additional cohorts will be decided following review of data of the previous cohorts.

Condition or disease Intervention/treatment Phase
Mitochondrial Diseases Mitochondrial Respiratory Chain Deficiencies MELAS Syndrome Mitochondrial Myopathies Drug: KL1333 Drug: Placebo Oral Tablet Phase 1

Detailed Description:

Part A: Eight healthy subjects will be studied in a single cohort (Group A1). Potential subjects will be screened to assess their eligibility to enter the study within 28 days prior to the first dose administration. Subjects will participate in 2 treatment periods, fasting or after consuming a standard high-fat breakfast. For each treatment period, subjects will reside at the Phase I clinical site from Days 1 to 3 (48 hours postdose). Subjects will return to the clinical site for outpatient visits on Days 4 and 5. There will be at least a 10 day washout between doses Additional single-dose cohorts may be enrolled based on data obtained from either Parts A or B.

Part B: Sixteen healthy subjects will be studied in 2 cohorts (Groups B1 and B2), with each cohort consisting of 8 subjects. Following review of safety, tolerability, and PK data, up to 3 additional dose cohorts of healthy subjects may be added to further explore the PK, safety, and tolerability of KL1333. Potential subjects will be screened to assess their eligibility to enter the study within 28 days prior to the first dose administration. All subjects will participate in 1 treatment period and will reside at the Phase I clinical site from Days -1 to 12 (48 hours post final dose). Subjects will return to the clinical site for outpatient visits on Days 13 and 14. On Day 1, 6 subjects will be randomised to receive KL1333 and 2 subjects will be randomised to receive placebo. Subjects will return for a Follow-up visit on Day 15, 5 days after their final dose.

Part C: A total of 8 patients diagnosed with any mitochondrial disease will be enrolled in this part of the study. Part C may start after the dose selection conference has been completed for the final cohort of Part B, at a daily dose no higher than the highest well-tolerated dose in Part B. Potential study patients will be screened to assess their eligibility to enter the study within 35 days prior to the first dose administration. Patients will reside at the clinical site from Days -1 to 2 and Days 10 to 11 and return to the clinical site for outpatient visits on Days 4 and 8. It is planned for patients to receive study drug once daily on Days 1 to 10. Patients will return for a Follow-up visit on Day 15, 5 days after their final dose.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 72 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase Ia/Ib, Multiple-site Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KL1333 After a Single and Multiple Ascending Oral Doses in Healthy Subjects and Patients With Primary Mitochondrial Disease
Actual Study Start Date : March 18, 2019
Estimated Primary Completion Date : March 18, 2020
Estimated Study Completion Date : March 18, 2020


Arm Intervention/treatment
Experimental: KL1333
25 and 100 mg KL1333 encapsulated tablets for daily oral dosing
Drug: KL1333
25 and 100 mg KL1333 encapsulated tablets

Placebo Comparator: Matching placebo
25 and 100 mg KL placebo encapsulated tablets for daily oral dosing
Drug: Placebo Oral Tablet
25 and 100 mg placebo encapsulated tablets




Primary Outcome Measures :
  1. Safety: incidence and severity of AEs [ Time Frame: Day 15 ]
  2. Safety: incidence of laboratory abnormalities, based on haematology, clinical chemistry, and urinalysis test results [ Time Frame: Day 15 ]
  3. Safety: 12 lead ECG parameters [ Time Frame: Day 15 ]
  4. Safety: Number of participants with clinically significant abnormal vital signs measurements [ Time Frame: Day 15 ]
  5. Safety: Number of participants with clinically significant abnormal physical examinations [ Time Frame: Day 15 ]

Secondary Outcome Measures :
  1. PK: area under the curve, AUC0 ∞ [ Time Frame: Day 1 ]
  2. PK: AUC over a dosing interval (AUC0 τ) [ Time Frame: Days 1 and 10 ]
  3. PK: temporal change parameter (TCP; AUC0 τ/AUC0-∞) [ Time Frame: Days 1 and 10 ]
  4. PK: Cmax [ Time Frame: Day 1 ]
  5. PK: time of the Cmax (Tmax) [ Time Frame: Day 1 ]
  6. PK: minimum observed plasma concentration (Cmin) [ Time Frame: Days 1 and 10 ]
  7. PK: apparent plasma terminal elimination half life (t1/2) [ Time Frame: Days 1 and 10 ]
  8. PK: mean residence time (MRT) [ Time Frame: Days 1 and 10 ]
  9. PK: apparent total plasma clearance (CL/F) [ Time Frame: Days 1 and 10 ]
  10. PK: apparent volume of distribution during the terminal phase (Vz/F) [ Time Frame: Days 1 and 10 ]

Other Outcome Measures:
  1. NAD+/NADH concentrations and ratio (part B and C) [ Time Frame: Days 10 and 15 ]
    Biomarker

  2. FGF21 and GDF15 concentrations (part B and C) [ Time Frame: Days 10 and 15 ]
    Biomarker

  3. Lactate/pyruvate concentrations and ratio (part B and C) [ Time Frame: Days 10 and 15 ]
    Biomarker

  4. Newcastle Mitochondrial Disease Adult Scale (NMDAS) (part C) [ Time Frame: Day 10 ]
    Assessment of mitochondrial disease. The NMDAS is a validated clinical rating scale designed to capture the natural history of mitochondrial disease. The NMDAS includes 3 domains: current function, system specific involvement, and current clinical, assessed on 6-point Likert-type scale from 0 to 5, as well as a fourth section including a score for the 12-Item Short Form Survey-Version 2.

  5. Clinician Global Impression (CGI) (part C) [ Time Frame: Day 10 ]
    Assessment of illness severity, global improvement or change, and therapeutic response.The CGI is a 3-item observer-rated scale that measures illness severity, global improvement or change, and therapeutic response. The CGI is rated on a 7-point Likert-type scale, with the severity of illness scale using a range of responses from 1 (normal) to 7 (amongst the most severely ill patients).

  6. Patient Global Impression-Improvement (PGI-I) (part C) [ Time Frame: Day 10 ]
    Patient reported assessment of severity of illness. The PGI-I is a patient-rated scale using a 7-point Likert-type scale, with the severity of illness scale using a range of responses from 1 (normal) to 7 (amongst the most severely ill patients). An item about the patient's worst symptom will be included in the assessment for this study.

  7. Daily Fatigue Impact Severity (D-FIS) (part C) [ Time Frame: Day 10 ]
    Assessment of fatigue. The D-FIS is a patient-rated scale developed to assess the symptom of fatigue as part of an underlying chronic disease or condition. The D-FIS includes 8 items assessed on 5-point Likert-type scale from 0 (no problem) to 4 (extreme problem).

  8. Quality of Life in Neurological Disorders Fatigue Scale (Neuro-QoL Fatigue) (part C) [ Time Frame: Day 10 ]
    Assessment of fatigue. The Neuro-QoL Fatigue is one of several scales that make up the Quality of Life in Neurological Disorders measurement system. It is a reliable and validated brief 19-item survey of fatigue, completed by the subject, with a recall period of the past 7 days. The 19 items are scored from 1 (never) to 5 (always) and consequently, Neuro-QoL Fatigue total scores range from 19 to 95, with higher scores indicating greater fatigue and greater impact of mitochondrial disease on activities.

  9. 30 Second Sit-to-Stand Test (part C) [ Time Frame: Day 10 ]
    Test



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria (selected):

Healthy subjects and patients with mitochondrial disease must satisfy all of the following criteria at the Screening visit unless otherwise stated:

  1. Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception.
  2. Able to comprehend and willing to sign an ICF and to abide by the study restrictions.
  3. Able to perform all protocol-specified assessments and comply with the study visit schedule.

    Additional inclusion criteria for healthy subjects:

  4. Males or females, of any race, between 18 and 65 years of age, inclusive.
  5. Weight ≥50 kg and body mass index between 18.0 and 32.0 kg/m2, inclusive.
  6. In good health, determined by no clinically significant findings from medical history, physical examination, 12 lead ECG, vital signs measurements, and clinical laboratory evaluations (congenital nonhaemolytic hyperbilirubinemia [eg, Gilbert's syndrome] is not acceptable) at Screening and Check in as assessed by the Investigator.

    Additional inclusion criteria for patients with mitochondrial disease:

  7. Males or females, of any race, between 18 and 75 years of age, inclusive.
  8. Body mass index between 15.0 and 32.0 kg/m2, inclusive.
  9. Any mitochondrial disease that has been genetically confirmed.
  10. Clinically stable, apart from symptoms associated with the diagnosis of mitochondrial disease, as determined by medical history, physical examination, 12 lead ECG, vital signs measurements, and clinical laboratory evaluations at Screening and Check-in as assessed by the Investigator.

Exclusion Criteria (selected):

Healthy subjects and patients with mitochondrial disease will be excluded from the study if they satisfy any of the following criteria at the Screening visit unless otherwise stated:

  1. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, including KL1333 or its excipients, unless approved by the Investigator.
  2. History of gastroesophageal reflux disease, gastric erosions, peptic ulcer disease, or gastrointestinal bleeding episodes.
  3. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs including cholecystectomy (uncomplicated appendectomy and hernia repair will be allowed).
  4. History of malignancy of any organ system other than localised basal cell carcinoma of the skin, treated or untreated, within 5 years prior to Screening, regardless of whether there is evidence of local recurrence or metastases.
  5. History of clinically significant illness (except for mitochondrial disease in the patients in Part C) or surgery within 4 weeks prior to Screening, as determined by the Investigator.
  6. History of alcoholism or drug/chemical abuse within 2 years prior to Screening.
  7. Alcohol consumption of >28 units per week for males and >21 units per week for females. One unit of alcohol equals ½ pint (285 mL) of beer or lager, 1 glass (125 mL) of wine, or 1/6 gill (25 mL) of spirits.
  8. Positive alcohol breath test result or positive urine drug screen (confirmed by repeat) at Screening or Check in.
  9. Positive hepatitis panel and/or positive human immunodeficiency virus test

Additional exclusion criteria for patients with mitochondrial disease:

  1. Use of idebenone or medications (prescription or nonprescription) that have effects on metabolism or unknown binding sites (eg, vitamin E, co-enzyme 10, arginine) within 35 days or 5 half-lives, whichever is longer, prior to the first dose.
  2. Use of prescription drugs within 14 days prior to dosing, with the exception of established therapy for mitochondrial disease and the treatment of associated disorders that has been stable for at least 7 days prior to the first dose, as approved by the Medical Monitor and Investigator, in consultation with the Sponsor.
  3. Uncontrolled diabetes mellitus, as determined by the Investigator. Creatinine clearance <45 mL/min as calculated by the Cockcroft-Gault equation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03888716


Contacts
Layout table for location contacts
Contact: Volunteer recruitment center Covance Leeds, RN +44(0)113 394 5200 Volunteer.Leeds@covance.com

Locations
Layout table for location information
United Kingdom
Covance Leeds Recruiting
Leeds, West Yorkshire, United Kingdom, LS2 9LH
Contact: Volunteer center Covance Leeds    +44(0)113 394 5200    Volunteer.Leeds@covance.com   
Sponsors and Collaborators
NeuroVive Pharmaceutical AB
Investigators
Layout table for investigator information
Study Director: Matilda Hugerth, MSc NeuroVive Pharmaceutical AB

Layout table for additonal information
Responsible Party: NeuroVive Pharmaceutical AB
ClinicalTrials.gov Identifier: NCT03888716     History of Changes
Other Study ID Numbers: KL1333 2018-102
First Posted: March 25, 2019    Key Record Dates
Last Update Posted: March 25, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: According to EMA rules.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by NeuroVive Pharmaceutical AB:
Mitochondrial Diseases
Mitochondrial Respiratory Chain Deficiencies
MELAS Syndrome
Mitochondrial Myopathies
Kearns-Sayre Syndrome
Ophthalmoplegia, Chronic Progressive External

Additional relevant MeSH terms:
Layout table for MeSH terms
Syndrome
Muscular Diseases
Mitochondrial Diseases
Mitochondrial Myopathies
MELAS Syndrome
Disease
Pathologic Processes
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Metabolic Diseases
Mitochondrial Encephalomyopathies
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Cerebral Small Vessel Diseases
Cerebrovascular Disorders
Vascular Diseases
Cardiovascular Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn